Kimball Electronics (KE) Q3 2026: Medical Sales Surge 17% as Indianapolis Facility Ramps
Kimball Electronics’ third quarter spotlighted a decisive pivot toward medical contract manufacturing, with normalized medical sales up 17% and the new Indianapolis facility set to drive future growth. Automotive and industrial segments showed mixed signals, as strategic investments and disciplined working capital management position the company for margin expansion in fiscal 2027. Management affirmed guidance, underscoring confidence in the medical vertical and ongoing M&A ambitions.
Summary
- Medical Expansion Accelerates: Medical vertical now 30% of portfolio, driving growth and margin focus.
- Operational Discipline Evident: Nine straight quarters of positive cash flow and improved inventory efficiency.
- Strategic Capital Deployment: Facility investments and M&A appetite position KE for long-term medical market leadership.
Business Overview
Kimball Electronics is a global contract manufacturer specializing in electronics and precision assembly for the medical, automotive, and industrial end markets. The company generates revenue by providing design, manufacturing, and supply chain services, with major segments including medical contract manufacturing organization (CMO), automotive electronics, and industrial systems. Medical now comprises 30% of sales, automotive 46%, and industrial 24%.
Performance Analysis
Third quarter results reflected a deliberate shift toward medical manufacturing, with normalized sales in the medical vertical up 17% year-over-year, marking the third consecutive quarter of double-digit growth. This segment reached $106 million, or nearly one-third of total revenue, a key milestone in the company’s diversification strategy. Sequential sales rose 3.4%, led by medical, while automotive and industrial posted declines compared to the prior year.
Gross margin improved by 70 basis points to 7.9%, driven by favorable mix and the ramp of higher-margin medical programs, though partially offset by costs associated with the new Indianapolis facility. Cash flow from operations remained robust for the ninth straight quarter, supported by a nine-day improvement in cash conversion days and an 8% year-over-year reduction in inventory. Share repurchases continued, with $4 million deployed in Q3, and liquidity remains strong at $358.5 million.
- Medical Outperformance: Asia medical sales grew over 20%, while North America and Europe contributed to broad-based expansion.
- Automotive Mixed Signals: European automotive programs ramped, but North American EV demand weakened due to legislative changes.
- Industrial Headwinds: HVAC and off-highway demand lagged in North America, partially offset by public safety and smart meters in Europe.
Margin improvement and working capital discipline signal operational resilience, even as segment volatility persists.
Executive Commentary
"Margins remained solid, and cash from operations was positive for the ninth consecutive quarter. We expect Q4 to be a good finish to the year, and we are affirming our guidance for fiscal 2026 with adjusted operating margin estimated to be at the high end of the range."
Rick Phillips, Chief Executive Officer
"Expenses will be higher in FY26 as we make strategic investments in business transformation, IT solutions that drive innovation and efficiency, and business development for the future."
Jana Kroon, Chief Financial Officer
Strategic Positioning
1. Medical CMO Focus and Facility Ramp
The Indianapolis facility, a 300,000 square foot medical manufacturing site, anchors the company’s strategic pivot, with production set to begin by year-end. Management is leveraging this asset to attract new and existing customers, supporting both “lift and shift” programs and organic growth. The facility’s advanced capabilities in injection molding and device assembly are designed to capture larger, higher-margin medical contracts.
2. Balanced Vertical Portfolio
Medical’s rise to 30% of sales is a deliberate move to reduce reliance on automotive and industrial cycles, with leadership targeting continued double-digit growth. Automotive remains exposed to macroeconomic swings and regulatory changes, while industrial is pressured by sector-specific demand declines.
3. Inorganic Growth and M&A Readiness
Management is actively pursuing M&A as a complement to organic growth, focusing on targets that offer geographic reach, technical capabilities, or customer access in medical manufacturing. The renewed $300 million revolver and ample liquidity enable decisive action on tuck-in acquisitions aligned with the medical CMO strategy.
4. Operational Efficiency and Working Capital
Continuous improvement in inventory management and cash conversion days demonstrates a disciplined approach to working capital, freeing up resources for strategic initiatives. This focus is crucial as new facility costs temporarily pressure gross margins before expected absorption in fiscal 2028.
5. Customer Acquisition and “Land and Expand” Playbook
Kimball is on track to add five new medical customers this year, with a strategy centered on securing initial programs and deepening relationships over time. The company’s “land and expand” model aims to grow wallet share with blue-chip clients, leveraging operational excellence to drive follow-on business.
Key Considerations
This quarter underscores Kimball Electronics’ transformation into a medical-centric contract manufacturer, with strategic investments and disciplined execution setting the stage for margin expansion and growth acceleration.
Key Considerations:
- Medical Ramp Timing: Facility costs will pressure margins in FY27 until new programs scale and fixed costs are absorbed.
- Automotive Demand Volatility: North American EV program softness and macro swings could limit near-term recovery despite strong European program ramps.
- Strategic M&A Optionality: Ample liquidity enables opportunistic M&A, but integration and value creation must be closely monitored.
- Competitive Pricing Discipline: Medical CMO pricing remains rational, but competitive intensity is high; scale and differentiation are key to sustaining margin.
- Geographic Diversification: Growth in Asia and Europe mitigates regional risk, but global macro and geopolitical factors remain unpredictable.
Risks
Margin pressure from the Indianapolis facility ramp will persist through FY27 until new business scales. Automotive remains vulnerable to global macro cycles, especially as legislative changes impact EV demand. Medical CMO competition is intense, and winning new logos is critical to fully utilizing capacity and driving margin recovery. Ongoing geopolitical events, such as the Middle East conflict, may disrupt supply chains and customer demand in certain end markets.
Forward Outlook
For Q4, Kimball Electronics guided to:
- Sales of $370 to $380 million
- Adjusted operating income margin between 4.4% and 4.6%
For full-year 2026, management affirmed guidance:
- Revenue range of $1.4 to $1.46 billion
- Adjusted operating income margin at the high end of 4.2% to 4.5%
Management highlighted several factors that shape the outlook:
- Medical vertical expected to outpace other segments in Q4, with further growth as the Indianapolis facility ramps.
- Monitoring war impacts, including higher freight, raw materials, and energy costs, especially in Europe and the Middle East.
Takeaways
Kimball Electronics is executing a strategic transition toward higher-growth, higher-margin medical manufacturing, with operational discipline and capital allocation supporting the pivot.
- Medical Momentum: Three consecutive quarters of double-digit medical growth validate the CMO pivot and support future margin expansion as new capacity comes online.
- Automotive and Industrial Headwinds: Segment volatility persists, but geographic and program diversity provide partial offsets to macro-driven softness.
- Future Watchpoint: Investors should track medical facility utilization, new customer wins, and the pace of M&A as key drivers of margin recovery and long-term growth.
Conclusion
Kimball Electronics’ third quarter marks a clear inflection in its business mix, with medical now the primary engine for growth and margin expansion. Disciplined execution, strategic investments, and a robust balance sheet position the company to capitalize on medical CMO opportunities, even as legacy segments face near-term uncertainty.
Industry Read-Through
Kimball’s results reinforce the accelerating shift of electronics contract manufacturing toward the medical sector, where regulatory complexity and supply chain reliability drive demand for scaled, specialized partners. Facility investments and “land and expand” models are becoming table stakes for contract manufacturers seeking wallet share with blue-chip medical clients. Automotive softness tied to EV demand volatility is a cautionary signal for peers exposed to global macro and regulatory swings. Disciplined working capital management and M&A readiness are emerging as key differentiators in a consolidating sector.